Link Expands Series A to 90 Million Dollars

Company Link Cell Therapies Event Type Series A Expansion Modality Logic-Gated CAR-T Asset LNK001 and Pipeline Programs Target CAIX/ENPP3; Undisclosed Colorectal Antigen Pair Disease Area Solid and Hematologic Cancers Summary Link Cell Therapies expanded its previously announced $60 million Series A to $90 million. The…